Abstract
Patients with High-Grade Serous Ovarian Cancer (HGSOC) exhibit varied responses to treatment, with 20-30% showing de novo resistance to platinum-based chemotherapy. While hematoxylin-eosin (H&E) pathological slides are used for routine diagnosis of cancer type, they may also contain diagnostically useful information about treatment response. Our study demonstrates that combining H&E-stained Whole Slide Images (WSIs) with proteomic signatures using a multimodal deep learning framework significantly improves the prediction of platinum response in both discovery and validation cohorts. This method outperforms the Homologous Recombination Deficiency (HRD) score in predicting platinum response and overall patient survival. The study sets new performance benchmarks and explores the intersection of histology and proteomics, highlighting phenotypes related to treatment response pathways, including homologous recombination, DNA damage response, nucleotide synthesis, apoptosis, and ER stress. This integrative approach has the potential to improve personalized treatment and provide insights into the therapeutic vulnerabilities of HGSOC.
Competing Interest Statement
Zoltan Szallasi is an inventor on a patent used in the myChoice HRD assay.
Clinical Protocols
https://github.com/csabaiBio/HGSOC_platinum_response
Funding Statement
This work was supported by the National Research, Development, and Innovation Office of Hungary within the framework of the MILAB Artificial Intelligence National Laboratory (RRF-2.3.1-21-2022-00004) and the Data-Driven Health Division of National Laboratory for Health Security (RRF-2.3.1-21-2022-00006) and by the European Union (Grant Agreement Nr. 10109571, SECURED Project) and OTKA K128780. Further support was provided by the Stipendium Hungaricum Program under the Tempus Public Foundation. It was also supported by the Research and Technology Innovation Fund (KTIA_NAP_13-2014-0021 and 2017-1.2.1-NKP-2017-00002 to Z.S.), Breast Cancer Research Foundation (BCRF-23-159 to Z.S.), The Danish Cancer Society (R325-A18809 and R342-A19788 to Z.S.), The Danish Council for Independent Research - Health and Disease (2034-00205B to Z.S.), Basser Foundation (to Z.S.), NIH Grant 1 P01 CA228696-01A1 to Z.S.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
No new data was generated during this study. TCGA data is found at https://portal.gdc.cancer.gov/projects/TCGA-OV proteomics is found at https://www.sciencedirect.com/science/article/pii/S0092867416306730 supplementary information. HGSOC data is found at https://www.cancerimagingarchive.net/collection/ptrc-hgsoc/, proteomics data is found at https://www.dropbox.com/scl/fi/99t2ely8jtte5wtg4dzr1/processed_data.zip?rlkey=yc0xt6kn6hughftw6f8q2f24p&e=1&dl=0
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
4 Data availability
No new data was generated during this study. We release our splits of patients and cohorts in the supplementary information.
